Published in Invest New Drugs on January 29, 2008
Discovery of anticancer agents of diverse natural origin. Pure Appl Chem (2009) 2.00
Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer. PLoS One (2011) 0.86
Improved efficacy of acylfulvene in colon cancer cells when combined with a nuclear excision repair inhibitor. Chem Res Toxicol (2013) 0.76
Enantioselective total synthesis of (-)-acylfulvene and (-)-irofulven. J Org Chem (2009) 0.75
The search for synergy: a critical review from a response surface perspective. Pharmacol Rev (1995) 8.24
Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. Curr Biol (2000) 3.34
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst (1994) 2.92
DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene (2003) 2.10
Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts. Cancer Treat Rep (1987) 1.25
Anti-tumour compounds illudin S and Irofulven induce DNA lesions ignored by global repair and exclusively processed by transcription- and replication-coupled repair pathways. DNA Repair (Amst) (2002) 1.17
Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. J Biol Chem (2002) 1.14
Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114). Biochem Pharmacol (1997) 1.07
Induction of topoisomerase I cleavage complexes by 1-beta -D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. Proc Natl Acad Sci U S A (2000) 1.06
Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells. Clin Cancer Res (2004) 1.05
Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery (1999) 1.03
Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res (1997) 1.02
Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I. Clin Cancer Res (2002) 1.02
(Hydroxymethyl)acylfulvene: an illudin derivative with superior antitumor properties. J Nat Prod (1996) 1.01
Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF). Biochem Pharmacol (2000) 0.96
Preclinical evaluation of illudins as anticancer agents. Cancer Res (1987) 0.96
ATM-dependent CHK2 activation induced by anticancer agent, irofulven. J Biol Chem (2004) 0.96
Depurinating acylfulvene-DNA adducts: characterizing cellular chemical reactions of a selective antitumor agent. J Am Chem Soc (2007) 0.92
Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. Invest New Drugs (2004) 0.91
Apoptosis of colorectal adenocarcinoma induced by 5-FU and/or IFN-gamma through caspase 3 and caspase 8. Int J Oncol (1999) 0.91
Investigating the role of stereochemistry in the activity of anticancer acylfulvenes: synthesis, reductase-mediated bioactivation, and cellular toxicity. J Med Chem (2006) 0.90
Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins. Cancer Res (1999) 0.90
Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells. Unusually high sensitivity of ERCC2 and ERCC3 DNA helicase-deficient mutants in comparison to other chemotherapeutic agents. Biochem Pharmacol (1994) 0.90
NADPH alkenal/one oxidoreductase activity determines sensitivity of cancer cells to the chemotherapeutic alkylating agent irofulven. Clin Cancer Res (2004) 0.89
Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells. Cancer Chemother Pharmacol (2005) 0.89
Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines. Biochem Pharmacol (1999) 0.87
Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft. Eur J Cancer (1998) 0.87
Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients. Clin Cancer Res (2004) 0.86
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. Cancer Res (1999) 0.85
Characterization of MGI 114 (HMAF) histiospecific toxicity in human tumor cell lines. Cancer Chemother Pharmacol (1999) 0.84
Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria. Biochem J (2001) 0.84
Cytotoxic effects of MGI 114 are independent of tumor p53 or p21 expression. Anticancer Res (1999) 0.83
A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecol Oncol (2005) 0.83
The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs (1996) 0.82
Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units. Anticancer Drugs (1999) 0.82
Irofulven induces replication-dependent CHK2 activation related to p53 status. Biochem Pharmacol (2006) 0.81
5-FU-induced apoptosis correlates with efficacy against human gastric and colon cancer xenografts in nude mice. Anticancer Res (1997) 0.80
Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents. Invest New Drugs (1996) 0.80
Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan. Leukemia (2000) 0.79
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. J Clin Oncol (2000) 0.79
Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model. Eur J Cancer (2000) 0.79
Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent. Biochem Pharmacol (2003) 0.79
Microscopic metastasis of a human lung carcinoma cell line in athymic nude mice: isolation of a metastatic variant. Int J Cancer (1987) 0.78
MGI 114: augmentation of antitumor activity when combined with topotecan. J Pediatr Hematol Oncol (2000) 0.77
Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial. Am J Clin Oncol (2005) 0.77
Irofulven induces apoptosis in breast cancer cells regardless of caspase-3 status. Breast Cancer Res Treat (2002) 0.77
Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts. Cancer Chemother Pharmacol (1991) 0.77
Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models. Cancer Chemother Pharmacol (2004) 0.76
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors. Invest New Drugs (2006) 0.76
Irofulven (6-hydroxymethylacylfulvene, MGI 114)-induced apoptosis in human pancreatic cancer cells is mediated by ERK and JNK kinases. Anticancer Res (2002) 0.76
Enhanced antitumor activity of irofulven in combination with antimitotic agents. Invest New Drugs (2002) 0.76
Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft. Anticancer Drugs (2000) 0.75
Irofulven (6-hydroxymethylacylfulvene, MGI 114) induces caspase 8 and 9-mediated apoptosis in human pancreatic adenocarcinoma cells. Anticancer Res (2001) 0.75
Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C. Cancer Chemother Pharmacol (2002) 0.75
Nonresponsiveness of the metastatic human lung carcinoma MV522 xenograft to conventional anticancer agents. Anticancer Res (1995) 0.75
Schedule dependent toxicity and efficacy of combined gemcitabine/paclitaxel treatment in mouse adenocarcinoma. J Cancer Res Clin Oncol (2000) 0.75
Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. Prostate (2004) 0.75
Fludarabine monophosphate reduces the incidence and severity of graft-versus-host disease in a murine model of bone marrow transplantation. Blood (1997) 0.75
Additive action of gemcitabine (2',2'-difluorodeoxycytidine) and 2-chlorodeoxyadenosine on murine leukemias L1210 and P388. Cancer Invest (1999) 0.75
Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol Chem (2005) 1.18
Anti-tumour compounds illudin S and Irofulven induce DNA lesions ignored by global repair and exclusively processed by transcription- and replication-coupled repair pathways. DNA Repair (Amst) (2002) 1.17
Multifunctional roles for the PH domain of Dbs in regulating Rho GTPase activation. J Biol Chem (2003) 1.16
SmgGDS is a guanine nucleotide exchange factor that specifically activates RhoA and RhoC. J Biol Chem (2011) 1.13
High-throughput screening for small-molecule inhibitors of LARG-stimulated RhoA nucleotide binding via a novel fluorescence polarization assay. J Biomol Screen (2009) 0.98
Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model. Cancer Chemother Pharmacol (2008) 0.84
Enhanced antitumor activity of irofulven in combination with antimitotic agents. Invest New Drugs (2002) 0.76
Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C. Cancer Chemother Pharmacol (2002) 0.75